Integer Holdings Corporation Stock Price and Value Analysis

Integer Holdings Corporation (NYSE:ITGR) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Integer Holdings Corporation to reach your target.

Target type

ITGR Free Cash Flow Trend

Free Cash Flow trendline for ITGR
Free Cash Flow trendline for Integer Holdings Corporation
CSV

Based on historical returns, we believe that Integer Holdings Corporation can grow its free cash at a rate of about 3%. That's positive!

AdvantagesDisadvantagesNeutral
None.
  • This company is making money at a modest rate.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the ITGR Numbers

ITGR Price
(Integer Holdings Corporation stock price per share)
$126.97
[?] ITGR Fair Price
(based on intrinsic value)
$51.38
[?] ITGR Safety Price (based on a variable margin of safety) $30.83
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 110% higher than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Medical Devices stocks
[?] Free Cash Flow Jitter 39%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Recent Insider Activity

Open-market buys and sells reported by Integer Holdings Corporation's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2024-05-24 Hinrichs James F. Sell 9,603 $122.44

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 3,432,036 shares shorted. With 28,900,796 shares available for purchase and an average trading volume over the past 10 trading days of 732,630, it would take at least 4.7 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 1114483 52.1
2010 1114483 59
2011 1114483 70.5
2012 1114483 40
2013 1114483 33.1
2014 1114483 56.6
2015 1114483 -17.9
2016 1114483 67.9
2017 1114483 111
2018 1114483 123
2019 1114483 117
2020 1114483 132
2021 1114483 109
2022 1114483 62.8
2023 1114483 112
2024 1114483 125
2025 1114483 107

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 14 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $1,928 million against net income of $1,049 million, or 1.84 times. Net income was negative in 3 of the 17 years, and those years are left out of the ratio.

In 2025, operating cash flow was 1.91 times net income, compared with 2.52 times for the earliest three years (2009 to 2011).

In 2025, capital expenditures were $91 million, 46.4% of operating cash flow of $196 million, which leaves an estimated $105 million after capex. Across the 17 years with reported capex, it averaged 42.3% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Cash conversion in 2025 was 1.91, at least 0.25 under the 2.52 earliest three-year ratio. Gaps like this come from non-cash gains or from cash tied up in receivables, inventory or other working capital.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 -9 71.8 19.7 n/a
2010 33.1 76.9 16.1 2.32
2011 33.1 89.9 22.5 2.71
2012 -4.8 64.8 41.1 n/a
2013 36.3 56.8 18.9 1.56
2014 55.5 81.3 24.8 1.47
2015 -7.6 12.5 44.6 n/a
2016 6 106 58.6 17.70
2017 66.7 149 47.3 2.24
2018 168 167 44.9 1.00
2019 96.3 165 48.2 1.72
2020 77.3 181 46.8 2.35
2021 96.8 157 53.5 1.62
2022 66.4 116 74.7 1.75
2023 90.7 180 120 1.99
2024 120 205 105 1.71
2025 103 196 91 1.91

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $522 million in 2009 and $1,854 million in 2025, a compound annual growth rate of 8.2% over 16 years.

Revenue rose 8.0% from 2024 to 2025.

Our estimated free cash flow was $107 million in 2025, 5.8% of revenue. In 2009 the estimated margin was 10.0%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 522 52.1 10.0%
2010 533 59 11.1%
2011 569 70.5 12.4%
2012 646 40 6.2%
2013 664 33.1 5.0%
2014 688 56.6 8.2%
2015 800 -17.9 -2.2%
2016 1,387 67.9 4.9%
2017 1,462 111 7.6%
2018 1,215 123 10.1%
2019 1,258 117 9.3%
2020 1,073 132 12.3%
2021 1,221 109 8.9%
2022 1,331 62.8 4.7%
2023 1,556 112 7.2%
2024 1,717 125 7.3%
2025 1,854 107 5.8%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $17.2 million against total liabilities of $1,664 million, or 1.0% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 48.8% of total assets in 2025, compared with 45.1% in 2010, an increase of 3.7 percentage points.

Stockholders equity was $1,747 million in 2025, compared with $427 million in 2010, a rise of 309.2%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 3.4% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 777 22.9 350 427
2011 881 36.5 414 467
2012 890 20.3 409 481
2013 890 35.5 349 542
2014 955 76.8 342 613
2015 2,982 82.5 2,132 851
2016 2,833 52.1 2,107 725
2017 2,848 44.1 1,955 893
2018 2,327 25.6 1,266 1,060
2019 2,353 13.5 1,201 1,152
2020 2,372 49.2 1,101 1,271
2021 2,582 17.9 1,228 1,355
2022 2,794 24.3 1,377 1,417
2023 2,943 23.7 1,424 1,519
2024 3,078 46.5 1,459 1,619
2025 3,411 17.2 1,664 1,747

Price Versus Our Estimated Value

Positive free cash flow appears in 16 of the 17 fiscal years we hold for Integer Holdings Corporation from its current SEC filer.

Free cash flow from the first three years of data averaged $60.5 million, and from the last three $115 million: a sharp rise.

Free cash flow is volatile from year to year, with a variability measure of 39%.

Integer Holdings Corporation is priced at $126.97, above our fair value estimate of $51.38 and its safe value of $30.83.

We do not have a dividend yield for Integer Holdings Corporation.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 110% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is in line with the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to Integer Holdings Corporation, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Integer Holdings Corporation (ITGR) 4,317 42.6 - - 147% above
ICU Medical (ICUI) 4,315 72.2 - 1.4% 29% above
LivaNova PLC (LIVN) 4,998 26.0 - - 317% above
Merit Medical Systems (MMSI) 5,053 31.6 - 1.1% 117% above
Haemonetics Corporation (HAE) 5,472 53.2 - 1.7% 132% above
UFP Technologies (UFPT) 2,253 29.7 - 0.1% 395% above
Teleflex Incorporated (TFX) 6,408 79.6 0.8% 5.7% 24% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1114483.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 1 of the 17 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: ITGR annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in ITGR

Does Integer Holdings Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: ITGR

This example shows how we apply the Trendshare checklist to ITGR: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 126.97
    • Market cap: $4.3B
    • EPS: 2.98
  2. Step 2 — Valuation checks

    • P/E: 42.607
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.